Atorvastatin calcium formulation
Pro Research Analysisby 
Searched over 200M research papers
Analyzed relevant papers
Atorvastatin Calcium Formulation: Improving Solubility, Bioavailability, and Patient Compliance
Challenges in Atorvastatin Calcium Formulation: Solubility and Bioavailability
Atorvastatin calcium, a widely used statin for lowering cholesterol, faces significant formulation challenges due to its poor aqueous solubility and low oral bioavailability, often less than 12%. It is highly soluble in acidic pH and is absorbed mainly in the upper gastrointestinal tract, but undergoes extensive first-pass metabolism, limiting its effectiveness when taken orally Rani2021Dong2018Dixit2024.
Lipid-Based and Nano-Formulations: Niosomes, SNEDDS, and SEDDS
To address these challenges, several advanced drug delivery systems have been developed:
- Niosomes: These vesicular systems, made using nonionic surfactants and cholesterol, have been shown to improve the absorption and oral bioavailability of atorvastatin calcium. Niosomes can also reduce toxicity and modify pharmacokinetics, making them promising carriers for this drug .
- Self-Nanoemulsifying Drug Delivery Systems (SNEDDS): SNEDDS and their solid forms (S-SNEDDS) use oils, surfactants, and cosurfactants to enhance the solubility and dissolution profile of atorvastatin calcium. These systems achieve high drug release rates (over 90%) and maintain stability under accelerated conditions . Similarly, self-emulsifying drug delivery systems (SEDDS) have demonstrated improved in vitro and in vivo performance, significantly reducing serum lipid levels in animal models .
Solid Dispersion and Deep Eutectic Solvent (DES) Approaches
- Solid Dispersions: Using hydrophilic carriers like Poloxamer 188, solid dispersions of atorvastatin calcium have been shown to convert the drug to a more soluble form, resulting in higher dissolution rates and improved oral bioavailability compared to standard tablets . Sustained-release tablets using solid dispersion techniques with polymers such as hydroxypropyl methylcellulose and gums also enhance solubility and provide prolonged drug release, improving patient compliance .
- Deep Eutectic Solvents (DES): Formulating atorvastatin calcium with DES (e.g., choline chloride and carboxylic acids) can further enhance solubility and bioavailability. DES-based formulations offer delayed and diffusion-controlled drug release, which may allow for less frequent dosing and better therapeutic outcomes .
Fast Dissolving and Orodispersible Tablets
- Orodispersible and Fast Dissolving Tablets: These formulations use superdisintegrants like Ac Di Sol, menthol, and starch malonate to achieve rapid disintegration (as fast as 14–21 seconds) and high drug release (up to 98.6%). Such tablets are especially beneficial for patients with swallowing difficulties and can improve convenience and compliance 3Singh2024.
Liquisolid Tablets and Solid Form Considerations
- Liquisolid Tablets: By using solvents like PEG 400 and carrier materials such as Avicel and Neusilin, liquisolid tablets of atorvastatin calcium show improved dissolution rates compared to marketed products, without drug-excipient interactions .
- Solid Form Screening: The physical form of atorvastatin calcium (e.g., trihydrate vs. anhydrate) can impact manufacturing and product quality. Careful screening and compatibility studies ensure that the chosen form remains stable and that the final tablets meet pharmacopeial standards for weight, hardness, disintegration, and dissolution .
Conclusion
A variety of innovative formulation strategies—including niosomes, SNEDDS/SEDDS, solid dispersions, DES, liquisolid systems, and fast-dissolving tablets—have been developed to overcome the poor solubility and low bioavailability of atorvastatin calcium. These approaches not only enhance drug absorption and therapeutic efficacy but also improve patient compliance through more convenient and effective dosage forms Rani2021Reddy20183+7 MORE.
Sources and full results
Most relevant research papers on this topic
1
Formulation and evaluation of atorvastatin calcium niosomes
Niosomes successfully developed using nonionic surfactants show promise as promising drug carriers and delivery modules for atorvastatin calcium, improving oral bioavailability and reducing toxicity.
In Vitro Study
2021·
1citation
·N. Rani et al.PDF
2
Formulation and In Vitro Characterization of Solid-self Nanoemulsifying Drug Delivery System of Atorvastatin Calcium
The solid-self nanoemulsifying drug delivery system (S-SNEDDS) improves atorvastatin calcium's solubility and bioavailability, with a stable formulation and 91.7% drug release.
In Vitro Study
2018·
11citations
·M. Reddy ·
DOI
PDF
4
Liquisolid Tablets Formulation of Atorvastatin Calcium Using Polyethylene Glycol 400 as Solvent and Some Carrier Materials
The developed liquisolid tablet formulation using PEG 400 and various carrier materials significantly improves the dissolution of atorvastatin calcium, with no drug-excipient interactions observed.
2020·
5citations
·Y. Windriyati et al.PDF
5
Formulation and evaluation of atorvastatin calcium trihydrate Form I tablets
Atorvastatin calcium trihydrate Form I tablets were successfully formulated and evaluated, with no interactions between ACT and excipients and acceptable quality parameters.
2025·
1citation
·Karen Andrea Salazar-Barrantes et al.PDF
6
Preparation, characterization, and in vitro/vivo evaluation of polymer-assisting formulation of atorvastatin calcium based on solid dispersion technique
ATC-P188 solid dispersions show potential for enhancing higher oral bioavailability of atorvastatin calcium compared to Lipitor, improving drug solubility and pharmacokinetics.
In Vitro Study
2018·
47citations
·Wenxiang Dong et al.PDF
8
Formulation and Evaluation of Fast Dissolving Tablets of Atorvastatin Calcium using Starch Malonate
Incorporating Starch Malonate as a superdisintegrant in Atorvastatin Calcium fast dissolving tablets effectively promoted rapid disintegration and drug release, offering potential advantages in patient convenience and compliance.
2024·
0citations
·Sakshi Singh et al.PDF